Following a decade-long scale up of
malaria control through vector control interventions, the introduction of rapid diagnostic tests and highly efficacious
Artemisinin-based Combination
Therapy (ACT) along with other measures, global
malaria incidence declined significantly. The recent development of
artemisinin resistance on the Cambodia-Thailand border, however, is of great concern. This review encompasses the background of
artemisinin resistance in Plasmodium falciparum, its situation, especially in the Greater Mekong Sub-region (GMS), and the responses taken to overcome this resistance. The difficulties in defining resistance are presented, particularly the necessity of measuring the clinical response to
artemisinins using the slow parasite-clearance phenotype. Efforts to understand the molecular basis of
artemisinin resistance and the search for molecular markers are reviewed. The markers, once identified, can be applied as an efficient tool for resistance surveillance. Despite the limitation of current surveillance methods, it is important to continue vigilance for
artemisinin resistance. The therapeutic efficacy "in vivo study" network for monitoring
antimalarial resistance in the GMS has been strengthened. GMS countries are working together in response to
artemisinin resistance and aim to eliminate all P. falciparum parasites. These efforts are crucial since a resurgence of
malaria due to
drug and/or insecticide resistance, program cuts, lack of political support and donor
fatigue could set back
malaria control success in the sub-region and threaten
malaria control and elimination if resistance spreads to other regions.